P
Peter T. Nieh
Researcher at Emory University
Publications - 48
Citations - 1838
Peter T. Nieh is an academic researcher from Emory University. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 20, co-authored 48 publications receiving 1618 citations. Previous affiliations of Peter T. Nieh include Emory Healthcare.
Papers
More filters
Journal Article
Initial Experience with the Radiotracer Anti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid with PET/CT in Prostate Carcinoma
David M. Schuster,John R. Votaw,Peter T. Nieh,Weiping Yu,Jonathon A. Nye,Viraj A. Master,F. DuBois Bowman,Muta M. Issa,Mark M. Goodman +8 more
TL;DR: Anti-(18)F-FACBC is a promising radiotracer for imaging prostate carcinoma and should be investigated in normal and pathologic tissue and develop a clinical imaging strategy for initial staging and restaging.
Journal ArticleDOI
Hyperspectral imaging and quantitative analysis for prostate cancer detection.
Hamed Akbari,Luma V. Halig,David M. Schuster,Adeboye O. Osunkoya,Viraj A. Master,Peter T. Nieh,Georgia Z. Chen,Baowei Fei,Baowei Fei +8 more
TL;DR: This imaging method may be able to help physicians to dissect malignant regions with a safe margin and to evaluate the tumor bed after resection and may lead to advances in the optical diagnosis of prostate cancer using HSI technology.
Journal ArticleDOI
Anti-3-[18F]FACBC Positron Emission Tomography-Computerized Tomography and 111In-Capromab Pendetide Single Photon Emission Computerized Tomography-Computerized Tomography for Recurrent Prostate Carcinoma: Results of a Prospective Clinical Trial
David M. Schuster,Peter T. Nieh,Ashesh B. Jani,Rianot Amzat,F. DuBois Bowman,Raghuveer Halkar,Viraj A. Master,Jonathon A. Nye,Oluwaseun Odewole,Adeboye O. Osunkoya,Bital Savir-Baruch,Pooneh Alaei-Taleghani,Mark M. Goodman +12 more
TL;DR: Better diagnostic performance was noted for anti-3-[(18)F]FACBC positron emission tomography-computerized tomography than for ProstaScint® ((111)In-capromab pendetide) single photon emission computerized tomographic-computerizing tomography for prostate carcinoma recurrence.
Journal ArticleDOI
Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer
Tore Bach-Gansmo,Cristina Nanni,Peter T. Nieh,Lucia Zanoni,Tronde Velde Bogsrud,Heidi Sletten,Katrine Andersen Korsan,Jesse Kieboom,Funmilayo Tade,Oluwaseun Odewole,Albert Chau,Penelope Ward,Mark M. Goodman,Stefano Fanti,David M. Schuster,Frode Willoch +15 more
TL;DR: Fluciclovine (18F) was well tolerated and the safety profile was not altered following repeat administration, and it was able to detect local and distant prostate cancer recurrence across a wide range of prostate specific antigen values.
Journal ArticleDOI
Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Oluwaseun Odewole,Funmilayo Tade,Peter T. Nieh,Bital Savir-Baruch,Ashesh B. Jani,Viraj A. Master,Peter J. Rossi,Raghuveer Halkar,Adeboye O. Osunkoya,Oladunni Akin-Akintayo,Chao Zhang,Zhengjia Chen,Mark M. Goodman,David M. Schuster,David M. Schuster +14 more
TL;DR: The diagnostic performance of fluciclovine PET/CT in recurrent prostate cancer is superior to that of CT and fluco-PET/CT provides better delineation of prostatic from extraprostatic recurrence.